Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Blood (2024) 144 (Supplement 1): 636.

https://doi.org/10.1182/blood-2024-205421

Published: 2024

Journal Articles

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Steffen Krohn, Carina Lynn Gehlert, Dorothee Winterberg, Alexander Jochimsen, Ammelie Svea Boje, Natalie Baum, Claudia D Baldus, Monika Brüggemann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Gramatzki, Katja Klausz, Christian Kellner, Matthias Peipp

Blood (2024) 144 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2024-207737

Published: 2024

Journal Articles

A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies

Blood (2024) 144 (Supplement 1): 914.

https://doi.org/10.1182/blood-2024-210243

Published: 2024

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2023-185875

Published: 2023

Journal Articles

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Blood (2022) 140 (1): 45–57.

https://doi.org/10.1182/blood.2021014485

Published: 2022

Includes: Supplemental data

Journal Articles

An Inducible Leukemia-Associated Transcription Factor Facilitates Large-Scale Ex Vivo Generation of Functional Human Macrophages

Blood (2021) 138 (Supplement 1): 2805.

https://doi.org/10.1182/blood-2021-148336

Published: 2021

Journal Articles

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Katja Klausz, Carina Lynn Gehlert, Ammelie Svea Boje, Marta Lustig, Steffen Krohn, Syeda Maliha Ahmed, Christian Kellner, Thomas Valerius, Lenka Besse, Andrej Besse, Christoph Driessen, Martin Gramatzki, Matthias Peipp

Blood (2021) 138 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2021-152208

Published: 2021

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Judith Petersen, Thies Rösner, PhD, Max Kölling, Katja Klausz, PhD, Christian Kellner, PhD, Andreas Humpe, MD, George J Weiner, MD, Denis Martin Schewe, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2019) 134 (Supplement_1): 5305.

https://doi.org/10.1182/blood-2019-122940

Published: 2019

Journal Articles

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Fotini Vogiatzi, Dorothee Winterberg, Lennart Lenk, Swantje Buchmann, Gunnar Cario, Martin Schrappe, Matthias Peipp, Paulina Richter-Pechanska, Andreas E. Kulozik, Jana Lentes, Anke K. Bergmann, Thomas Valerius, Fabian-Simon Frielitz, Christian Kellner, Denis M. Schewe

Blood (2019) 134 (8): 713–716.

https://doi.org/10.1182/blood.2019000904

Published: 2019

Includes: Supplemental data

Journal Articles

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Fotini Vogiatzi, PhD, Julia Heymann, Thies Rösner, PhD, Lennart Lenk, PhD MSc, Gunnar Cario, MD, Martin Schrappe, MD PhD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Simon Bomken, MD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 4177.

https://doi.org/10.1182/blood-2018-99-114677

Published: 2018

Journal Articles

Targeting the Glyco-Antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B Cell Lymphoma and Plasma Cell Tumors

Katja Klausz, PhD, Amir Karimzadeh-Tabrizi, Malena Buck, Steffen Krohn, Anna-Kathrin Otte, PhD, Christian Kellner, PhD, Giorgio Alberto Croci, MD, Wolfram Klapper, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2018) 132 (Supplement 1): 4178.

https://doi.org/10.1182/blood-2018-99-118068

Published: 2018

Journal Articles

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Thorsten Ross, PhD, Uwe Reusch, PhD, Susanne Wingert, PhD, Torsten Haneke, PhD, Katja Klausz, PhD, Anna-Kathrin Otte, PhD, Natalie Schub, MD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Thomas Valerius, MD, Martin Gramatzki, MD, Matthias Peipp, PhD, Michael Tesar, PhD, Erich Rajkovic, PhD MBA, Martin Treder, PhD

Blood (2018) 132 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2018-99-118970

Published: 2018

Journal Articles

AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma

Thorsten Gantke, PhD, Uwe Reusch, PhD, Christian Kellner, PhD, Katja Klausz, PhD, Torsten Haneke, PhD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Anne Kerber, MD, Matthias Peipp, PhD, Martin Treder, PhD

Blood (2017) 130 (Supplement 1): 3082.

https://doi.org/10.1182/blood.V130.Suppl_1.3082.3082

Published: 2017

Journal Articles

CD75s Represents a Therapeutic Target for Antibody-Based Immunotherapy of B Cell Lymphoma and Multiple Myeloma

Katja Klausz, PhD, Malena Buck, Steffen Krohn, Renate Burger, PhD, Christian Kellner, PhD, Martin Gramatzki, MD, Matthias Peipp, PhD

Blood (2017) 130 (Supplement 1): 1810.

https://doi.org/10.1182/blood.V130.Suppl_1.1810.1810

Published: 2017

Journal Articles

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL -rearranged acute lymphoblastic leukemia xenografts

Denis M. Schewe, Ameera Alsadeq, Cornelia Sattler, Lennart Lenk, Fotini Vogiatzi, Gunnar Cario, Simon Vieth, Thomas Valerius, Sophia Rosskopf, Fabian Meyersieck, Julia Alten, Martin Schrappe, Martin Gramatzki, Matthias Peipp, Christian Kellner

Blood (2017) 130 (13): 1543–1552.

https://doi.org/10.1182/blood-2017-01-764316

Published: 2017

Includes: Supplemental data

Journal Articles

An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Denis M Schewe, MD, Ameera Alsadeq, PhD, Gunnar Cario, MD, Simon Vieth, MD, Thomas Valerius, MD, Martin Schrappe, MD PhD, Martin Gramatzki, MD, Matthias Peipp, PhD, Christian Kellner, PhD

Blood (2016) 128 (22): 277.

https://doi.org/10.1182/blood.V128.22.277.277

Published: 2016

Journal Articles

The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Andreas Guenther, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2016) 128 (22): 4471.

https://doi.org/10.1182/blood.V128.22.4471.4471

Published: 2016

Journal Articles

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Anna Kretschmer, Stefan Lohse, PhD, Thies Rösner, PhD, Marco J.H. Jansen, Christian Kellner, PhD, Matthias Peipp, PhD, Mark S Cragg, PhD, Ameera Alsadeq, PhD, Denis M Schewe, MD, Jeanette H.W. Leusen, PhD, Thomas Valerius, MD

Blood (2016) 128 (22): 1835.

https://doi.org/10.1182/blood.V128.22.1835.1835

Published: 2016

NARROW

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

An Inducible Leukemia-Associated Transcription Factor Facilitates Large-Scale Ex Vivo Generation of Functional Human Macrophages

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Targeting the Glyco-Antigen CD75s with the Tetravalent, Fc-Engineered Antibody 'Ebu-141 Tetra' Induces Potent Killing of B Cell Lymphoma and Plasma Cell Tumors

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

AFM26 - Targeting B Cell Maturation Antigen (BCMA) for NK Cell-Mediated Immunotherapy of Multiple Myeloma

CD75s Represents a Therapeutic Target for Antibody-Based Immunotherapy of B Cell Lymphoma and Multiple Myeloma

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL -rearranged acute lymphoblastic leukemia xenografts

An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only